Full Press Release Details
Announces Enrollment of First Patient in its ACRobat
Phase III Trial of Piclidenoson in Rheumatoid Arthritis
TIKVA, Israel, October 30, 2017 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing
a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the first
patient has been enrolled and dosed in its Phase III ACRobat trial to evaluate its lead drug candidate, Piclidenoson (CF101),
as a first line treatment and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for
rheumatoid arthritis.
estimated 90% of rheumatoid arthritis patients receive MTX at some point in their disease. However, studies show that up to 50%
of patients stop taking MTX due to reasons including drug intolerance, minor and major side effects, and lack of efficacy, creating
a significant need for a new, safe and effective treatment option in the rheumatoid arthritis treatment market which is forecast
to reach $34.6 billion by 2020. Piclidenoson compares favorably with MTX based on an analysis of data from Phase III trials that
evaluated MTX in patients with no prior systemic therapy.
primary endpoint of ACRobat is low disease activity after 12 weeks of treatment in patients dosed with Piclidenoson compared to
those dosed with MTX. Piclidenoson at 1 mg and 2 mg, or placebo, will be administered twice daily, and MTX or placebo will be
administered once weekly. The total study duration will be 24 weeks in order to provide more data on long term efficacy and safety.
This randomized, double-blind, active and placebo-controlled study will enroll approximately 500 patients through clinical sites
in Europe, Israel and Canada.
the first patient in our Phase III ACRobat trial marks a significant milestone for Can-Fite. We believe Piclidenoson is a potentially
superior option to the standard of care, MTX, and we believe that rheumatologists are looking for a safer and more effective alternative,"
stated Can-Fite CEO Dr. Pnina Fishman.
Piclidenoson (CF101)
is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic
index demonstrated in Phase II clinical studies. Piclidenoson is currently under development for the treatment of autoimmune inflammatory
diseases. It is being evaluated in a Phase III study as a first line treatment, to replace MTX, in the treatment of rheumatoid
arthritis. Piclidenoson is also slated to enter a Phase III study in the treatment of moderate-to-severe psoriasis in 2018.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of inflammatory diseases, cancer, and NAFLD/NASH. The
Company's lead drug candidate Piclidenoson is currently being evaluated in a global Phase III trial as a first line therapy for
rheumatoid arthritis. Piclidenoson is also slated to enter a Phase III trial for psoriasis in early 2018. Can-Fite's liver cancer
drug CF102 concluded patient enrollment in a Phase II study for patients with liver cancer, and it is slated to enter Phase II
for the treatment of non-alcoholic steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation in the U.S. and Europe
and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. CF102
has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's
third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating
additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with
experience in over 1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,
strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking
statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"
"expect," "intend," "plan," "may," "should" or "anticipate" or their
negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly
to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings
made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval
of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially
from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities
or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could
cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but
are not limited to: the initiation, timing, progress and results of our preclinical studies, clinical trials and other product
candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete
our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of
other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates;
our ability to establish and maintain corporate collaborations; the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our business without infringing the intellectual property rights of
others; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; competitive companies,
technologies and our industry; statements as to the impact of the political and security situation in Israel on our business;
and risks and other risk factors detailed in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition,
Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other
factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether
as a result of new information, future events or otherwise.